SCHEMBL1798310

SCHEMBL1798310

Cc1[nH]c(C(=O)N2CCC(C(=O)NCCCN(C)C)CC2)c(C)c1-c1nc2ccc(C(=O)c3ccccc3)cc2[nH]1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGDS O60760 2/20 0.54
PDGFRB P09619 1/20 0.40
FGFR1 P11362 1/20 0.40
PDGFRA P16234 1/20 0.40
FLT1 P17948 1/20 0.40
FGFR3 P22607 1/20 0.40
KDR P35968 1/20 0.40
LMNA P02545 3/20 0.40
ABL1 P00519 2/20 0.40
ALDH1A1 P00352 2/20 0.39
HPGD P15428 2/20 0.39
POLB P06746 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
FLT3 P36888 1/20 0.39
CHEK2 O96017 2/20 0.39
ESR1 P03372 1/20 0.38
KDM4E B2RXH2 1/20 0.38
MAPT P10636 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1799662 0.96 HPGDS (0.56) HPGDSPDGFRBFGFR1PDGFRAFLT1
SCHEMBL1798299 0.94 HPGDS (0.47) HPGDSPDGFRBFGFR1PDGFRAFLT1
SCHEMBL1800606 0.91 HPGDS (0.54) HPGDSKDRLMNAABL1ALDH1A1
SCHEMBL1799661 0.90 HPGDS (0.48) HPGDSPDGFRBFGFR1PDGFRAFLT1
SCHEMBL1797252 0.87 HPGDS (0.57) HPGDSPDGFRBFGFR1KDRLMNA
SCHEMBL1801711 0.86 HPGDS (0.51) HPGDSLMNAABL1ALDH1A1HPGD
SCHEMBL1801409 0.85 HPGDS (0.60) HPGDSPDGFRBFGFR1KDRLMNA
SCHEMBL1800604 0.85 HPGDS (0.46) HPGDSPDGFRBFGFR1PDGFRAFLT1
SCHEMBL1800835 0.85 HPGDS (0.64) HPGDSLMNAABL1ALDH1A1HPGD
SCHEMBL1801605 0.83 HPGDS (0.58) HPGDSALDH1A1HPGDPOLBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1911755-B1 BENZOIMIDAZOLE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHETASE TAIHO PHARMACEUTICAL CO LTD (JP) 2011-09-14 EP disclosed
US-7951956-B2 Benzoimidazole compound capable of inhibiting prostaglandin D synthetase TAIHO PHARMACEUTICALS CO., LTD. (JP) 2011-05-31 US disclosed
US-20090281098-A1 BENZOIMIDAZOLE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHETASE TAIHO PHARMACEUTICAL CO., LTD. (JP) 2009-11-12 US disclosed
EP-1911755-A1 BENZOIMIDAZOLE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHETASE TAIHO PHARMACEUTICAL CO., LTD. (JP) 2008-04-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281098-A1 BENZOIMIDAZOLE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHETASE PTGS1, PTGIS, PTGES HPGDS 5/4885PDGFRB 892/4885FGFR1 371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.